Yazarlar : Triulzi DJ, Assmann SF, Strauss RG, et al.

Yayın : Blood

Yayın Yılı : 2012

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22496156

Konu : Transfüzyon

Literatür İçeriği :  

Abstract

Platelet characteristics such as platelet dose (number of platelets per transfusion), platelet source (apheresis vs. pooled), platelet donor-recipient ABO compatibility, and duration of platelet storage can affect post transfusion platelet increments, but it is unclear whether these factors impact platelet transfusion efficacy on clinical bleeding. We performed secondary analyses of platelet transfusions given in the PLADO prospective randomized study of three platelet dosing strategies (ClinicalTrials.gov #NCT00128713) which included 1272 platelet-transfused hematology-oncology patients who received 6031 prophylactic platelet transfusions. The primary outcome of these secondary analyses was time from first transfusion to first WHO ≥grade 2 bleeding determined by daily assessment. Platelet transfusion increments were assessed at 0.25-4 hours and 16-32 hours after platelet transfusion. There were 778 patients evaluable for analysis of time to bleeding. Adjusted models showed that randomized dose strategy, platelet source, ABO matching status and duration of storage did not predict this outcome. Platelet increments were generally higher for transfusions of apheresis platelets, ABO identical platelets, and platelets stored 3 days vs. 4-5 days. Thus, although platelet source, ABO compatibility, and duration of storage exert a modest impact on both absolute and corrected post transfusion platelet increments, they have no measurable impact on prevention of clinical bleeding.

Literatür Arşivi